TNBI · Tanke Biosciences Corp
Market Cap
$266,481
Shares
13.32M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.01
Open$0.02
Day$0.01–0.02
52W close$0.01–0.06
Avg vol 30d39K
Short int411 · 0.0% float · 1.0d
Short vol76%
DataFeb 2020–Sep 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$22.96M
Trailing 12 months
Net income (TTM)
−$1.64M
Trailing 12 months
Revenue growth YoY
-39.0%
Year over year
Operating margin
-0.2%
Trailing 12 months
P / E (TTM)
0.1
Trailing earnings · reciprocal yield 793.7%
FCF yield
-2,299.1%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$3.18M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+0.0%
Year over year
Price change (1Y)
-37.0%
Trailing year
Short interest
—
Latest settlement
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.4 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−62%
below
Price vs 50-day avg
−75%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−83%
trailing
6-month return
0%
trailing
YTD return
−67%
this year
Relative strength
−18%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Fundamentals
Revenue growth
+20%
Y/Y
Gross margin
35%
contracting
EPS growth
−171%
Y/Y
Balance sheet
$4.1M
net cash
Quant / Vol
risk profile
Volatility
610%
annualized · 1-yr
Max drawdown
−94%
past year
ATR
96.0%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−62%
Bearish
Price vs 50-day avg
−75%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
No clear signal
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Flat
No 13F holder data
Insider flow
Flat
No net insider activity over 90 days
Short interest
Flat
0.00% of float · ▬ 0.0% MoM · 1.0 days cover
Volume signal
Reversal watch
High volume on a down day — possible exhaustion
Institution breadth
Steady
No 13F holder history
Price context
position in its 52-week range
Range low $0
Now $0 · 0%
Range high $0
vs 200-day avg -62%
vs 50-day avg -75%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Asset Management — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TNBI
this stock
Tanke Biosciences Corp
|
$266,481 | -66.7% | +19.8% | — | 0.0% |
|
BLK
BlackRock, Inc.
|
$344.91B | -1.5% | +16.2% | 25.4 | 0.6% |
|
BX
Blackstone Inc.
|
$94.92B | -18.6% | +9.2% | 28.4 | 2.9% |
|
KKR
KKR & Co. Inc.
|
$91.80B | -23.0% | -11.0% | — | 1.5% |
|
BN
BROOKFIELD Corp /ON/
|
$83.40B | -19.0% | — | — | 1.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionShort & Settlement
Financials
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TNBI | -33.3% | -83.3% | +0.0% | -46.8% | -66.7% |
| SPY | +0.6% | -0.8% | +18.2% | -0.6% | +11.8% |
| vs SPY | -34.0% | -82.5% | -18.2% | -46.2% | -78.5% |